Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Miraki Innovation Launches $175M Medical Technology Breakthrough Fund

Executive Summary

Christopher Velis, co-founder of Auris Health and founder of Miraki Innovation has launched the Medical Technology Breakthrough Fund, a $175m fund to help finance and build the next-generation of medtech companies.

You may also be interested in...



SAGES 2019: Spotlighting Competitive Robotic Systems And Procedures

Surgical robotics giant Intuitive Surgical will soon face competition from Medtronic and Verb Surgical. With the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting on the way in Baltimore, MD this week, Wells Fargo analyst Larry Biegelsen offers an outlook on competitive robotic systems and the rising popularity by surgeons to use robotics systems in hernia, bariatric, cholecystectomy and colorectal procedures.

Johnson & Johnson Diversifies Robotic Efforts With Auris Health Aquisition

Johnson & Johnson will acquire robotic startup Auris Health for $3.4bn in cash, plus milestones payments of up to $2.4bn. Auris developed the FDA-cleared Monarch platform, which is expected to rival Intuitive Surgical's robotic-assisted bronchoscope device, Ion, awaiting FDA clearance.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel